Original Article
Effects of different doses of dexmedetomidine in combination with sevoflurane for laryngeal mask airway placement in children during laparoscopic inguinal hernia repair

Hongxin Ji¹, Shiqiong He²*, Anxue Li¹, Jiawei Wang¹, Qiuyu Zhu¹, Haoxiang Sun¹

Departments of ¹Anesthesiology, ²Gynaecology, Longgang District People’s Hospital of Shenzhen, Shenzhen, Guangdong Province, China. *Equal contributors.

Received March 27, 2020; Accepted September 1, 2020; Epub December 15, 2020; Published December 30, 2020

Abstract: Objective: The aim of this study was to investigate the effects of 2 μg/kg and 4 μg/kg of dexmedetomidine (Dex) pretreatment on the median effective concentration (EC₅₀) of sevoflurane for successful laryngeal mask airway (LMA) placement in children during laparoscopic inguinal hernia repair. Methods: 82 cases of children (aged from 2 to 6 years, and ASA at I or II grade) were recruited and randomly divided into 3 groups, including control (n=25), 2 μg/kg of Dex (n=28), and 4 μg/kg of Dex (n=29). After sublingual administration of 0.9% saline and Dex, probabilistic unit regression analysis was applied to calculate the EC₅₀ and the corresponding 95% confidence interval (95% CI) of sevoflurane in children for successful LMA placement. Results: The rates of parental separation satisfaction and mask acceptance satisfaction in the 4 μg/kg of Dex (100%, 89.66%) group were significantly higher than those in the control (8.0%, 0.0%) and 2 μg/kg of Dex (64.29%, 46.43%) groups. The positive rates of LMA placement among the control (48.0%), 2 μg/kg of Dex (46.43%), and 4 μg/kg of Dex (44.83%) groups had no significant difference. The EC₅₀ and 95% CI of sevoflurane in the 4 μg/kg of Dex group (1.55%, 1.42-1.66%) was remarkably lower than those in the control (2.02%, 1.89-2.14%) and 2 μg/kg of Dex (1.73%, 1.61-1.85%) groups. Compared with the control group, 2 μg/kg and 4 μg/kg of Dex could decrease the EC₅₀ of sevoflurane in children for successful LMA placement by 14.36% and 23.27%, respectively. Conclusion: Dex pretreatment effectively reduces the EC₅₀ of sevoflurane for successful LMA placement in children during laparoscopic inguinal hernia repair.

Keywords: Sevoflurane, dexmedetomidine, effects, LMA, pretreatment

Introduction
Laryngeal mask airway (LMA) placement is a common alternative to the endotracheal tube and face mask for insuring the respiratory tract in elective operation under general anesthesia in children [1, 2]. The forfeit of protective respiratory tract reflexes and blockade of the upper airway after general anesthesia can be life-threatening. LMA placement can offer a close against the glottis without changing the mucosal pressures, which also has a port for gastric drain tube to prohibit aspiration [3, 4]. Emerging evidences have suggested that sevoflurane is a useful and suitable inhalational drug for induction and preservation of anesthesia in children [5]. During LMA placement, sevoflurane is applied as a prevalent induction drug based on the depressant effects for the airway reflexes. However, separating children from their parents before induction of anesthesia and receiving mask inhalation to induce LMA implantation is a major challenge for anesthesiologists worldwide.

Dexmedetomidine (Dex) is a highly selective α₂-adrenergic agonist, which shows analgesic and sedative effects with minimal respiratory depression [6, 7]. Recent studies have shown that Dex presents with a high bioavailability for drug administration [8]. On one hand, Dex is suitable for producing sedation before pediatric anesthesia, and its sedative effect is better than midazolam [7, 9]. On the other hand, Dex
Dexmedetomidine combined with sevoflurane for LMA placement

as a general anesthetic agent can inhibit sympathetic activities, obviously reduce the stress responses during LMA placement, and decrease the dose required for general anesthesia [10]. For instance, Yoo et al [11] demonstrated that pretreatment with 1 μg/kg of Dex reduces the propofol requirement by 38% for boosting LMA placement without prolonged hemodynamic instability and respiratory depression. Nellore et al [12] suggested that Dex significantly reduces the induction doses of propofol for LMA placement.

To date, there is no dose-ranging study of Dex pretreatment on the median effective concentration (EC_{50}) of sevoflurane for successful LMA placement in children during laparoscopic inguinal hernia repair. Therefore, our study intended to refer the modified sequential method to determine the effects of 2 μg/kg and 4 μg/kg of Dex pretreatment on the EC_{50} of sevoflurane, and to provide references for the clinical application of Dex combined sevoflurane for insertion of LMA in children.

Materials and methods

Patients selection and experimental grouping

82 cases of children (aged from 2 to 6 years, ASA at I-II grade, and BMI at 18-25 kg/m^2) who underwent laparoscopic inguinal hernia repair with elective general anesthesia were recruited and selected, and divided into three groups by random number method, including control (n=25), 2 μg/kg of Dex (n=28), and 4 μg/kg of Dex (n=29). Inclusion criteria: children underwent laparoscopic inguinal hernia. Exclusion criteria: bronchial asthma, history of upper respiratory tract infection within 2 weeks, allergy to Dex, arrhythmia, congenital heart disease, mental illness, and congenital and neurological disorders. This study was approved by the Ethics Committee of Longgang District People’s Hospital of Shenzhen and registered at the China Clinical Trial Registration Center (No. ChiCTR-IOD-17011601). The parents of each child were informed of the risk and signed the informed consent form.

Anesthesia process

All children were banned from eating 6-8 h and drinking 2-3 h before surgery, and were established venous indwelling needles before sur-
Dexmedetomidine combined with sevoflurane for LMA placement

points. 1-2 points indicated dissatisfaction, and 3-4 points indicated satisfaction. LMA placement reaction criteria: any one of cough, body movement, and throat or whole body conscious body movements within 1 min of LMA placement was positive; no response was negative. The heart rate (HR), systolic blood pressure (SBP) and blood oxygen saturation (SaO₂) were recorded before sublingual administration and every 5 min after sublingual administration. The incidence of adverse reactions such as hypotension, bradycardia, respiratory depression, nausea, and vomiting were observed. Clinical indicators before and after operation were also recorded, including operation time, hospitalization time, postoperative analgesic application, postoperative infection, recurrence of hernia, chronic pain, local discomfort, local hematoma, and urine retention.

Table 1. Comparison of general clinical indicators

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number of cases</th>
<th>Gender (man/female)</th>
<th>ASA grade (I/II)</th>
<th>Average ages (years)</th>
<th>BMI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>25</td>
<td>16/9</td>
<td>18/7</td>
<td>4.15 ± 1.78</td>
<td>20.33 ± 1.85</td>
</tr>
<tr>
<td>2 μg/kg of Dex</td>
<td>28</td>
<td>19/9</td>
<td>20/8</td>
<td>4.19 ± 1.54</td>
<td>21.82 ± 1.59</td>
</tr>
<tr>
<td>4 μg/kg of Dex</td>
<td>29</td>
<td>21/8</td>
<td>20/9</td>
<td>4.27 ± 1.80</td>
<td>20.94 ± 1.72</td>
</tr>
</tbody>
</table>

χ² or F P

0.44 0.07 0.52 1.61 0.80 0.97 0.77 0.34

Statistical analysis

Statistical analysis was performed using SPSS 19.0 statistical software (SPSS, Chicago, IL, USA). Measurement data were expressed as the mean ± standard deviation (SD). One-way analysis of variance was used for comparing the differences between the three groups. Count data were expressed as percentages, and the differences were assessed by using chi-square (χ²) test. Probability unit regression analysis was applied to calculate the EC₅₀ and corresponding 95% CI of sevoflurane in children with successful LMA placement. Sequential test plots were drawn by using Microsoft Excel 2007 software (Microsoft Corp, Seattle, WA, USA). P<0.05 was considered statistically significant.

Results

General clinical indicators

A total of 82 cases of children were enrolled in the study, 25 cases of children were in the control group, 28 cases of children were in the 2 μg/kg of Dex group, and 29 cases were of children in the 4 μg/kg of Dex group. The constituent ratios of gender (man/female) in the control, 2 μg/kg of Dex, and 4 μg/kg of Dex groups were 16/9, 19/9, and 21/8, respectively. The constituent ratios of ASA grade (I/II) in the control, 2 μg/kg of Dex, and 4 μg/kg of Dex groups were 18/7, 20/8, and 20/9, respectively. The average ages in the control, 2 μg/kg of Dex, and 4 μg/kg of Dex groups were 4.15 ± 1.78, 4.19 ± 1.54, and 4.27 ± 1.80 years, respectively. The BMI in the control, 2 μg/kg of Dex, and 4 μg/kg of Dex groups was 20.33 ± 1.85, 21.82 ± 1.59, and 20.94 ± 1.72, respectively. There were no significant differences in constituent ratio of gender and ASA grade, average ages, and BMI among the control, 2 μg/kg of Dex, and 4 μg/kg of Dex groups (Table 1). All children were able to tolerate sublingual administration without significant discomfort. Before the induction of anesthesia, the SpO₂ was greater than 95% without significant respiratory depression. No adverse reactions such as bradycardia, hypotension, nausea and vomiting were observed. There was no significant difference in operation and hospitalization time among the three groups. All children had no postoperative infection, scrotal hematoma, scrotal effusion, and urinary retention. After 6 to 24 months of follow-up, all children had no obvious discomfort or foreign body sensation in the groin area, and no case recurred.

Dex pretreatment increases the rates of parental separation satisfaction and mask acceptance satisfaction

As shown in Table 2, the rates of parental separation satisfaction and mask acceptance satisfaction in the 4 μg/kg of Dex (100%, 89.66%) group were significantly higher than those in the control (8.0%, 0.0%) and 2 μg/kg of Dex (64.29%, 46.43%) groups (P<0.05). The
Dexmedetomidine combined with sevoflurane for LMA placement

Table 2. Comparison of the rates of parental separation satisfaction and mask acceptance satisfaction

<table>
<thead>
<tr>
<th>Groups</th>
<th>Number of cases</th>
<th>Parental separation satisfaction (n, %)</th>
<th>Mask acceptance satisfaction (n, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>25</td>
<td>2 (8.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>2 μg/kg of Dex</td>
<td>28</td>
<td>18 (64.29%)</td>
<td>13 (46.43%)</td>
</tr>
<tr>
<td>4 μg/kg of Dex</td>
<td>29</td>
<td>29 (100%)</td>
<td>26 (89.66%)</td>
</tr>
<tr>
<td>(\chi^2)</td>
<td>-</td>
<td>47.62</td>
<td>43.29</td>
</tr>
<tr>
<td>P</td>
<td>-</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Figure 1. Sequential test charts of sevoflurane for inhibiting LMA placement in children. The number of positive/negative cases of LMA placement in the control (A), 2 μg/kg of Dex (B), and 4 μg/kg of Dex (C) groups were 12/13, 13/15, and 13/16. The positive rates of LMA placement among the control (48.0%), 2 μg/kg of Dex (46.43%), and 4 μg/kg of Dex (44.83%) groups had no significant difference.

Dex pretreatment decreases the EC\(_{50}\) of sevoflurane for successful LMA placement in children

The EC\(_{50}\) and 95% CI of sevoflurane in the 4 μg/kg of Dex group (1.55%, 1.42-1.66%) were markedly lower than those in the control (2.02%, 1.89-2.14%) and 2 μg/kg of Dex (1.73%, 1.61-1.85%) groups (Figure 2, P<0.05). Compared with the control group, 2 μg/kg and 4 μg/kg of Dex reduced the EC\(_{50}\) of sevoflurane in children for successful LMA placement by 14.36% and 23.27%, respectively.

Discussion

Dex injection (pH at 4.5-7.0) contains no preservatives and chemical stabilizers, which is a colorless and odorless clear liquid and is suitable for oral and nasal administration [14]. Ilorla et al [15] reported that oral administration of Dex in adult volunteers has a bioavailability of only 16% due to first-pass effects, while intranasal administration has 65% bioavailability and the bioavailability of sublingual administration is as high as 82%. Although partial swallowing may occur in the oral administration, the oral buccal mucosa absorbs of Dex can reach at an average of 56%, and it is more acceptable for children than nasal administration [16]. In this study, we gave 57 cases of children with Dex by
Dexmedetomidine combined with sevoflurane for LMA placement

Recent report by Sakurai et al [17] showed that 75% of children can achieve Ramsay sedation score of 5 points or more when 3-4 μg/kg of Dex was given 1 h before anesthesia. It was safe and effective to give 3-4 μg/kg of Dex 1 h before anesthesia, but the study did not evaluate the satisfaction of receiving a mask and LMA placement, and did not discuss the effects on the EC50 of sevoflurane after Dex administration. Therefore, our study was divided into the control, 2 μg/kg, and 4 μg/kg of Dex groups, and the sedation scores, mask inhalation-induced acceptance, and LMA placement reaction, and vital signs monitoring among the three groups were evaluated 1 h before anesthesia. Our results revealed that the satisfaction rates of sedation and masks in the 4 μg/kg of Dex group were 100% and 89.7%, which were higher than those in the control (8.0%, 0.0%) and the 2 μg/kg (64.29%, 46.43%) of Dex groups, respectively. The positive rates of LMA placement in control (48.0%), 2 μg/kg of Dex (46.43%), and 4 μg/kg of Dex (44.83%) groups have no statistical difference, indicating that 2 and 4 μg/kg of Dex have no effect on the positive reaction of mask placement. The possible reasons may be the following: 1) Dex has analgesic and sedative effects with minimal respiratory inhibition; 2) Dex can suppress sympathetic activities, and obviously reduce the stress responses during LMA placement; 3) Children are well tolerated with Dex; 4) Other factors. In addition, all children had no adverse reactions such as hypotension, bradycardia, and hypoxemia, indicating that Dex is absorbed into the blood through the oral mucosa, and it can achieve effective sedation and slow side effects.

Furthermore, we referred to Savla et al's report [18] to set the initial end-tidal concentration of sevoflurane to 2% and the concentration gradient to 0.2%. The EC50 of sevoflurane was determined by using a modified sequential method. The results showed that the inhalation of sevoflurane inhibited the LMA placement response of 2.02%, which was similar to that of He et al study [19] (2.01%), but higher than Aantaa et al's research [20]. Aantaa et al reported that the EC50 of sevoflurane satisfied for LMA placement was 1.57% in children aged 4 to 12 years old. The main reason might be the difference in ages, in addition to the research methods and criteria for evaluating the LMA placement reaction [21, 22]. Here, we found that 2 μg/kg of Dex and 4 μg/kg inhibited the LMA placement reaction with the EC50 of sevoflurane of 1.73% and 1.55%, respectively, which were 14.36% and 23.27% lower than that of the control group. These data indicated that Dex enhances the sedative effects of sevoflurane and significantly inhibits the stress response during LMA placement, thereby reducing the end-tidal concentration of sevoflurane.

In clinical application, some children did not cooperate, and spat out the drug solution immediately after administration, which affect-
Dexmedetomidine combined with sevoflurane for LMA placement

ed the sedative effect and should be noticed. In this study, we recommended a small amount (0.1-0.3 ml) of 50% glucose injection mixed with Dex injection for sublingual administration, so the children are more likely to receive without increasing the amounts of the drug and causing swallowing. At the same time, we should also notice clearly that this study only explored the dose-effects relationship of Dex combined with sevoflurane in the inhibition of LMA placement in children, and the dose-effects in other ages need further study.

In summary, our study demonstrated that Dex pretreatment effectively reduces the EC50 of sevoflurane for successful LMA placement in children, indicating that Dex combined with sevoflurane is the suitable induction agent of choice for insertion of LMA.

Acknowledgements

The work was supported by the Shenzhen Project of Science and Technology (No. JCYJ2016-0422141605247).

Disclosure of conflict of interest

None.

Address correspondence to: Anxue Li, Department of Anesthesiology, Longgang District People’s Hospital of Shenzhen, No. 53, Ai Xin Road, Longgang District, Shenzhen 518172, Guangdong Province, China. Tel: +86-755-28932833-6301; Fax: +86-755-28932833-6301; E-mail: lianxue135@126.com

References


Dexmedetomidine combined with sevoflurane for LMA placement